CO5640109A2 - Compuestos triciclicos inhibidores de la farnesisl proteino transferasa y composiciones farmaceuticas que los contienen - Google Patents
Compuestos triciclicos inhibidores de la farnesisl proteino transferasa y composiciones farmaceuticas que los contienenInfo
- Publication number
- CO5640109A2 CO5640109A2 CO03017118A CO03017118A CO5640109A2 CO 5640109 A2 CO5640109 A2 CO 5640109A2 CO 03017118 A CO03017118 A CO 03017118A CO 03017118 A CO03017118 A CO 03017118A CO 5640109 A2 CO5640109 A2 CO 5640109A2
- Authority
- CO
- Colombia
- Prior art keywords
- carbon
- carbon atom
- attached
- farnesisl
- transferasa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1.- Un compuesto de fórmulao una sal o solvato farmacéuticamente aceptable del mismo, en la cual:uno entre a, b, c y d representa a N ó N+O-, y los grupos restantes a, b, c y d representan a carbono, en la cual cada carbono tiene un grupo R1 ó R2 unido a dicho carbono; ó cada uno de a, b, c y d es carbono, en el cual cada carbono tiene un grupo R1 o R2 unido a dicho carbono;las líneas de puntos (---) representan enlaces opcionales;X representa a N ó CH cuando el enlace opcional está ausente y representa a C cuando el enlace opcional está presente;cuando el enlace opcional está presente entre el átomo de carbono 5 y el átomo de carbono 6, entonces hay sólo un sustituyente A unido al átomo de carbono 5 y hay sólo un sustituyente B unido al átomo de carbono 6 y A ó B es distinto de H;cuando el enlace opcional no está presente entre el átomo de carbono 5 y el átomo de carbono 6, entonces hay dos sustituyentes A unidos al átomo de carbono 5, y dos sustituyentes B unidos al átomo de carbono 6, en donde cada sustituyente A y cada sustituyente B se selecciona independientemente entre: (1) -H; (2) _R9; (3) -R9-C(O)-R9; (4) -R9 -CO2-R9a ; (5) -(CH2)pR26; (6) -C(O)N(R9)2, en donde cada R9 es igual o diferente; (7) -C(O)NHR9; (8) -C(O)NH-CH2-C(O)-NH2; ...
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22918300P | 2000-08-30 | 2000-08-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5640109A2 true CO5640109A2 (es) | 2006-05-31 |
Family
ID=22860141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO03017118A CO5640109A2 (es) | 2000-08-30 | 2003-02-27 | Compuestos triciclicos inhibidores de la farnesisl proteino transferasa y composiciones farmaceuticas que los contienen |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20020198216A1 (es) |
| EP (1) | EP1313725B1 (es) |
| JP (1) | JP2004513885A (es) |
| KR (1) | KR20030034161A (es) |
| CN (1) | CN100384837C (es) |
| AR (1) | AR033680A1 (es) |
| AT (1) | ATE359281T1 (es) |
| AU (2) | AU2001288451C1 (es) |
| BR (1) | BR0113675A (es) |
| CA (1) | CA2420673A1 (es) |
| CO (1) | CO5640109A2 (es) |
| DE (1) | DE60127846T2 (es) |
| EC (1) | ECSP034494A (es) |
| ES (1) | ES2284686T3 (es) |
| HK (1) | HK1054548B (es) |
| HU (1) | HUP0302942A3 (es) |
| IL (1) | IL154528A0 (es) |
| MX (1) | MXPA03001849A (es) |
| NO (1) | NO20030918L (es) |
| NZ (1) | NZ524246A (es) |
| PE (1) | PE20020486A1 (es) |
| PL (1) | PL361103A1 (es) |
| RU (1) | RU2293734C9 (es) |
| SK (1) | SK2292003A3 (es) |
| TW (1) | TWI268280B (es) |
| WO (1) | WO2002018368A1 (es) |
| ZA (1) | ZA200301545B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7342016B2 (en) | 2000-08-30 | 2008-03-11 | Schering Corporation | Farnesyl protein transferase inhibitors as antitumor agents |
| EP1383490B1 (en) * | 2001-03-14 | 2012-04-25 | Bristol-Myers Squibb Company | Combination of an epothilone analog and chemotherapeutic agents for the treatment of proliferative diseases |
| EP1435959A2 (en) * | 2001-10-09 | 2004-07-14 | University of Cincinnati | Inhibitors of the egf receptor for the treatment of thyroid cancer |
| US20030185831A1 (en) * | 2001-11-30 | 2003-10-02 | Schering Corporation | Methods of treating cancer using an FPT inhibitor and antineoplastic |
| EP1453513A1 (en) * | 2001-12-03 | 2004-09-08 | Schering Corporation | Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer |
| US20030195192A1 (en) * | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| US20040014744A1 (en) * | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
| EP2260846B1 (en) * | 2003-03-27 | 2018-11-28 | Lankenau Institute for Medical Research | Novel methods for the treatment of cancer |
| EP1628631A2 (en) * | 2003-06-05 | 2006-03-01 | Achkar, Charles C. | Methods of treating hyperproliferative cell disorders |
| WO2005001053A2 (en) * | 2003-06-09 | 2005-01-06 | Samuel Waksal | Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist |
| TW200510384A (en) * | 2003-08-07 | 2005-03-16 | Schering Corp | Novel farnesyl protein transferase inhibitors as antitumor agents |
| US7592466B2 (en) | 2003-10-09 | 2009-09-22 | Abbott Laboratories | Ureas having antiangiogenic activity |
| MX2007007611A (es) * | 2004-12-21 | 2007-09-04 | Schering Corp | Nuevos inhibidores de la farnesil protein-transferasa como agentes antitumorales. |
| CA2730190A1 (en) * | 2008-07-14 | 2010-01-21 | Queen's University At Kingston | Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer |
| EP3989956A1 (en) * | 2019-06-28 | 2022-05-04 | Anhui Ronghang Biotech Development Co., Ltd. | Compositions and methods for treatment of hepatitis b virus infection |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5089496A (en) * | 1986-10-31 | 1992-02-18 | Schering Corporation | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies |
| US5719148A (en) * | 1993-10-15 | 1998-02-17 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| PE92098A1 (es) * | 1996-07-31 | 1998-12-31 | Schering Corp | N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo |
| US6071907A (en) * | 1996-09-13 | 2000-06-06 | Schering Corporation | Tricyclic compounds useful as FPT inhibitors |
| US5925648A (en) * | 1997-07-29 | 1999-07-20 | Schering Corporation | Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase |
| JP2002533335A (ja) * | 1998-12-18 | 2002-10-08 | シェーリング コーポレイション | ファルネシルタンパク質トランスフェラーゼインヒビター |
-
2001
- 2001-08-27 AR ARP010104082A patent/AR033680A1/es unknown
- 2001-08-28 NZ NZ524246A patent/NZ524246A/en unknown
- 2001-08-28 AT AT01968188T patent/ATE359281T1/de not_active IP Right Cessation
- 2001-08-28 IL IL15452801A patent/IL154528A0/xx unknown
- 2001-08-28 AU AU2001288451A patent/AU2001288451C1/en not_active Ceased
- 2001-08-28 RU RU2003108865/04A patent/RU2293734C9/ru not_active IP Right Cessation
- 2001-08-28 MX MXPA03001849A patent/MXPA03001849A/es active IP Right Grant
- 2001-08-28 CA CA002420673A patent/CA2420673A1/en not_active Abandoned
- 2001-08-28 WO PCT/US2001/026792 patent/WO2002018368A1/en active Application Filing
- 2001-08-28 PE PE2001000865A patent/PE20020486A1/es not_active Application Discontinuation
- 2001-08-28 DE DE60127846T patent/DE60127846T2/de not_active Expired - Fee Related
- 2001-08-28 EP EP01968188A patent/EP1313725B1/en not_active Expired - Lifetime
- 2001-08-28 TW TW090121201A patent/TWI268280B/zh active
- 2001-08-28 SK SK229-2003A patent/SK2292003A3/sk not_active Application Discontinuation
- 2001-08-28 JP JP2002523486A patent/JP2004513885A/ja active Pending
- 2001-08-28 BR BR0113675-5A patent/BR0113675A/pt not_active IP Right Cessation
- 2001-08-28 HU HU0302942A patent/HUP0302942A3/hu unknown
- 2001-08-28 US US09/940,811 patent/US20020198216A1/en not_active Abandoned
- 2001-08-28 AU AU8845101A patent/AU8845101A/xx active Pending
- 2001-08-28 KR KR10-2003-7003012A patent/KR20030034161A/ko not_active Application Discontinuation
- 2001-08-28 CN CNB01818121XA patent/CN100384837C/zh not_active Expired - Fee Related
- 2001-08-28 ES ES01968188T patent/ES2284686T3/es not_active Expired - Lifetime
- 2001-08-28 PL PL01361103A patent/PL361103A1/xx unknown
-
2003
- 2003-02-25 ZA ZA200301549A patent/ZA200301545B/xx unknown
- 2003-02-26 EC EC2003004494A patent/ECSP034494A/es unknown
- 2003-02-27 CO CO03017118A patent/CO5640109A2/es active IP Right Grant
- 2003-02-27 NO NO20030918A patent/NO20030918L/no not_active Application Discontinuation
- 2003-07-11 HK HK03105016.6A patent/HK1054548B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5640109A2 (es) | Compuestos triciclicos inhibidores de la farnesisl proteino transferasa y composiciones farmaceuticas que los contienen | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
| AR046422A1 (es) | Acidos carboxilicos macrociclicos y acilsulfonamidas como inhibidores de la replicacion del vhc | |
| CO5570660A2 (es) | Indazolilpirrolotriazinas c-6 modificadas | |
| AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
| AR039124A1 (es) | Derivados de adamantano, procedimiento de preparacion y composiciones farmaceuticas que los contienen | |
| AR055041A1 (es) | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. | |
| KR950032180A (ko) | 3-페닐피롤리딘 유도체 | |
| AR045901A1 (es) | Glucocorticoesteroides especificos con actividades antiinflamatoria y antialergica,composiciones farmaceuticas que los contienen,y procedimientos para su preparacion, | |
| AR047056A1 (es) | Derivados de pirimidinas condensadas. composiciones farmacéuticas | |
| CO5580815A2 (es) | Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen | |
| AR053774A1 (es) | Derivados de sulfonilbencimidazol. composiciones farmaceuticas. | |
| RU2004132204A (ru) | Имидазоконденсированные соединения | |
| AR002240A1 (es) | Derivado de 2,4-oxazolidinadiona, composicion farmaceutica que lo comprende y metodo de preparacion del mismo. | |
| UY25142A1 (es) | Antagonistas del receptor ccr-3 | |
| CO5580746A2 (es) | Derivados de fenil-piperazina como inhibidores de la reabsorcion de la serotonina | |
| AR040080A1 (es) | Inhibidores del virus de la hepatitis c | |
| CO5611194A2 (es) | Inhibidores novedosos de la farnesil proteina transferasa como agentes antitumorales | |
| AR048266A1 (es) | Compuesto de benzazepina, composicion farmaceutica que lo comprende y su uso para prepararla | |
| ATE114670T1 (de) | Phenylamidinderivate als plättchenaggregationsinhibitoren. | |
| AR044650A1 (es) | Derivados de tiofeno - pirimidinona y su uso en la terapia de enfermedades que requieren la inhibicion de la enzima 17b-hidroxiesteroide-dehidrogenasa. | |
| NO20051282L (no) | Antitumorale analoger av lamellariner. | |
| KR960704876A (ko) | 혈소판 응집 저해 작용을 갖는 신규 화합물 (Novel Compound Having Platelet Aggregation Inhibitor Effect) | |
| AR053835A1 (es) | Tetrahidropiridoazepin - 8 - onas como moduladores del receptor de dopamina d2 y compuestos relacionados para el tratamiento de la esquizofrenia y otros trastornos del snc, composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |